FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012023442> ?p ?o ?g. }

• W2012023442 endingPage "85" @default.
• W2012023442 startingPage "77" @default.
• W2012023442 abstract "Bisphosphonates have been shown to be effective in lowering serum calcium levels in patients with cancer-associated hypercalcemia. 1-Hydroxy-3-(methylpentylamino)propylidenebisphosphonate (BM 21.0955) was developed as a third generation bisphosphonate and has been recently proven effective in animals and in patients with Paget's disease or tumor osteolysis. Thirty-six patients with cancer-associated hypercalcemia were treated with increasing doses (0.2-2.0 mg) of BM 21.0955 by single i.v. infusion over 4 h in a phase I trial. Six patients were rejected from analysis due to concomitant treatment with other bisphosphonates or chemotherapy. After rehydration and infusion of BM 21.0955 the mean serum calcium levels fell significantly (P < 0.001), from 3.29 +/- 0.49 mmol/l to 3.04 +/- 0.44 mmol/l until day 2 and normalized on day 6 (2.66 +/- 0.33 mmol/l). Serum calcium was reduced in all patients and normalized in 16. No symptomatic hypocalcemia occurred. Mean serum creatinine decreased significantly (P < 0.01), from 1.25 +/- 0.58 mg/dl (day 0) to 1.05 +/- 0.37 mg/dl (day 6). The mean urinary calcium/creatinine concentration fell significantly (P < 0.001), from 1.90 +/- 1.16 mM/mM (day 0) to 0.37 +/- 0.34 mM/mM/l (day 6). There were no subjective drug-related side effects during or after the infusion. Thirteen patients had elevations of morning body temperature above 38 degrees C. This was due to confirmed infections in five patients and possibly drug- or tumor-related in the other eight. We conclude from these preliminary results that a single infusion of BM 21.0955 is an effective and safe way to treat cancer-associated hypercalcemia." @default.
• W2012023442 created "2016-06-24" @default.
• W2012023442 creator A5006902955 @default.
• W2012023442 creator A5017788113 @default.
• W2012023442 creator A5041396751 @default.
• W2012023442 creator A5041530747 @default.
• W2012023442 creator A5041847990 @default.
• W2012023442 creator A5045311601 @default.
• W2012023442 creator A5049792647 @default.
• W2012023442 creator A5076041723 @default.
• W2012023442 creator A5090577453 @default.
• W2012023442 date "1993-08-01" @default.
• W2012023442 modified "2023-09-27" @default.
• W2012023442 title "Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia" @default.
• W2012023442 cites W101778309 @default.
• W2012023442 cites W1591022542 @default.
• W2012023442 cites W1965682822 @default.
• W2012023442 cites W1972544033 @default.
• W2012023442 cites W1977969585 @default.
• W2012023442 cites W1997629391 @default.
• W2012023442 cites W2006953927 @default.
• W2012023442 cites W2012291531 @default.
• W2012023442 cites W2024479120 @default.
• W2012023442 cites W2062992747 @default.
• W2012023442 cites W2071452230 @default.
• W2012023442 cites W2083258979 @default.
• W2012023442 cites W2092562224 @default.
• W2012023442 cites W2092958646 @default.
• W2012023442 cites W2117490971 @default.
• W2012023442 cites W2129002513 @default.
• W2012023442 cites W2144676407 @default.
• W2012023442 cites W2180059893 @default.
• W2012023442 cites W2231830033 @default.
• W2012023442 cites W2394562815 @default.
• W2012023442 cites W2470515069 @default.
• W2012023442 cites W62888693 @default.
• W2012023442 doi "https://doi.org/10.1016/s0169-6009(08)80219-x" @default.
• W2012023442 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8251767" @default.
• W2012023442 hasPublicationYear "1993" @default.
• W2012023442 type Work @default.
• W2012023442 sameAs 2012023442 @default.
• W2012023442 citedByCount "29" @default.
• W2012023442 crossrefType "journal-article" @default.
• W2012023442 hasAuthorship W2012023442A5006902955 @default.
• W2012023442 hasAuthorship W2012023442A5017788113 @default.
• W2012023442 hasAuthorship W2012023442A5041396751 @default.
• W2012023442 hasAuthorship W2012023442A5041530747 @default.
• W2012023442 hasAuthorship W2012023442A5041847990 @default.
• W2012023442 hasAuthorship W2012023442A5045311601 @default.
• W2012023442 hasAuthorship W2012023442A5049792647 @default.
• W2012023442 hasAuthorship W2012023442A5076041723 @default.
• W2012023442 hasAuthorship W2012023442A5090577453 @default.
• W2012023442 hasConcept C121608353 @default.
• W2012023442 hasConcept C126322002 @default.
• W2012023442 hasConcept C126894567 @default.
• W2012023442 hasConcept C134018914 @default.
• W2012023442 hasConcept C2776541429 @default.
• W2012023442 hasConcept C2776694085 @default.
• W2012023442 hasConcept C2776697488 @default.
• W2012023442 hasConcept C2777251235 @default.
• W2012023442 hasConcept C2779384505 @default.
• W2012023442 hasConcept C2780306776 @default.
• W2012023442 hasConcept C519063684 @default.
• W2012023442 hasConcept C71924100 @default.
• W2012023442 hasConcept C77411442 @default.
• W2012023442 hasConcept C90924648 @default.
• W2012023442 hasConceptScore W2012023442C121608353 @default.
• W2012023442 hasConceptScore W2012023442C126322002 @default.
• W2012023442 hasConceptScore W2012023442C126894567 @default.
• W2012023442 hasConceptScore W2012023442C134018914 @default.
• W2012023442 hasConceptScore W2012023442C2776541429 @default.
• W2012023442 hasConceptScore W2012023442C2776694085 @default.
• W2012023442 hasConceptScore W2012023442C2776697488 @default.
• W2012023442 hasConceptScore W2012023442C2777251235 @default.
• W2012023442 hasConceptScore W2012023442C2779384505 @default.
• W2012023442 hasConceptScore W2012023442C2780306776 @default.
• W2012023442 hasConceptScore W2012023442C519063684 @default.
• W2012023442 hasConceptScore W2012023442C71924100 @default.
• W2012023442 hasConceptScore W2012023442C77411442 @default.
• W2012023442 hasConceptScore W2012023442C90924648 @default.
• W2012023442 hasIssue "2" @default.
• W2012023442 hasLocation W20120234421 @default.
• W2012023442 hasLocation W20120234422 @default.
• W2012023442 hasOpenAccess W2012023442 @default.
• W2012023442 hasPrimaryLocation W20120234421 @default.
• W2012023442 hasRelatedWork W1844518445 @default.
• W2012023442 hasRelatedWork W1975979596 @default.
• W2012023442 hasRelatedWork W1999039650 @default.
• W2012023442 hasRelatedWork W2003842308 @default.
• W2012023442 hasRelatedWork W2064236298 @default.
• W2012023442 hasRelatedWork W2095093072 @default.
• W2012023442 hasRelatedWork W2133845634 @default.
• W2012023442 hasRelatedWork W2369552721 @default.
• W2012023442 hasRelatedWork W2369866637 @default.
• W2012023442 hasRelatedWork W4379179103 @default.
• W2012023442 hasVolume "22" @default.
• W2012023442 isParatext "false" @default.
• W2012023442 isRetracted "false" @default.

• next